{"id":176966,"date":"2025-09-29T06:50:14","date_gmt":"2025-09-29T06:50:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/176966\/"},"modified":"2025-09-29T06:50:14","modified_gmt":"2025-09-29T06:50:14","slug":"macquarie-tips-more-than-20-upside-for-this-asx-all-ords-healthcare-stock","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/176966\/","title":{"rendered":"Macquarie tips more than 20% upside for this ASX All Ords healthcare stock"},"content":{"rendered":"<p><img width=\"1200\" height=\"675\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2025\/08\/imaging-scans-16.9-1200x675.jpg\" class=\"attachment-full size-full wp-post-image\" alt=\"Doctor checking patient's spine x-ray image.\" decoding=\"async\" fetchpriority=\"high\"  \/><\/p>\n<p>Image source: Getty Images<\/p>\n<p>Strong growth in healthcare service provision in August signals good news for healthcare stocks, with Macquarie analysts tipping Integral Diagnostics Ltd (<a class=\"tickerized-link\" href=\"https:\/\/www.fool.com.au\/tickers\/asx-idx\/\" rel=\"nofollow noopener\" target=\"_blank\">ASX: IDX<\/a>) shares to pile on more than 20% in gains. <\/p>\n<p>Medicare statistics for August, compiled by Macquarie, show that pathology volumes grew by 7% year over year while imaging volumes were up 6%.<\/p>\n<p>This is good news for Integral Diagnostics, which provides diagnostic imaging services such as magnetic resonance imaging (MRI), ultrasound, and radiography at 145 sites across Australia and New Zealand.<\/p>\n<p>Macquarie said its &#8220;key pick remains IDX, for which we expect cost synergies, MRI deregulation and GP bulk billing incentive to support <a href=\"https:\/\/www.fool.com.au\/definitions\/earnings-per-share\/\" rel=\"nofollow noopener\" target=\"_blank\">earnings per share growth<\/a>&#8221;.<\/p>\n<p>Key downside risks to our thesis on IDX primarily relate to weaker-than-expected volume growth and\/or operating cost growth ahead of our expectations. Downside from the\u2026 merger would be less-than expected cost synergies from the group.<\/p>\n<p>Macquarie has an outperform rating on Integral Diagnostics shares and a price target of $3.40, compared to the current price of $2.81.<\/p>\n<p>The broker has a neutral rating on Australian Clinical Labs Ltd (<a class=\"tickerized-link\" href=\"https:\/\/www.fool.com.au\/tickers\/asx-acl\/\" rel=\"nofollow noopener\" target=\"_blank\">ASX: ACL<\/a>), although it flags that there is likely still some upside to that stock. Its price target is $2.90, compared with the current price of $2.49. <\/p>\n<p> Merger synergies better than expected <\/p>\n<p>In late 2024, Integral Diagnostics merged with Capitol Health in a scrip-based deal, which valued Capitol at $413 million.<\/p>\n<p>While releasing the company&#8217;s full-year financial results in August, Integral Managing Director Dr Ian Kadish said the integration of the company was delivering better than expected cost savings.<\/p>\n<p>FY25 was a transformational year for the company, including the merger with Capitol Health which was successfully completed on 20 December 2024. The integration of Capitol Health has proceeded to plan, with $7 million of synergies realised in FY25, representing annualised synergies of $14 million, significantly exceeding initial expectations of at least $10 million.<\/p>\n<p>Integral Diagnostics declared a fully franked final dividend of 4 cents per share, bringing the full year payout to 6.5 cents per share, with the <a href=\"https:\/\/www.fool.com.au\/definitions\/dividend\/\" rel=\"nofollow noopener\" target=\"_blank\">final dividend <\/a>to be paid on October 3. <\/p>\n<p>The company said in August that its focus for the current financial year was to drive organic earnings growth, &#8220;including relentless focus on radiologist recruitment and productivity, together with operational efficiency&#8221;.<\/p>\n<p>It would also seek to accelerate the use of artificial intelligence and teleradiology.<\/p>\n","protected":false},"excerpt":{"rendered":"Image source: Getty Images Strong growth in healthcare service provision in August signals good news for healthcare stocks,&hellip;\n","protected":false},"author":2,"featured_media":99264,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,8428,13955,137,500,7037,7038,7039,7040,72525,8430],"class_list":["post-176966","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-category-brokers","tag-category-healthcare-shares","tag-health","tag-healthcare","tag-partner-feeds-msn-9","tag-partner-feeds-newstex","tag-partner-feeds-sharesight","tag-partner-feeds-webull","tag-tickers_global-asx-idx","tag-tickers_global-asx-mqg"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/176966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=176966"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/176966\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/99264"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=176966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=176966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=176966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}